A Research Program Studying Treatment Effectiveness
and Outcomes in Schizophrenia and Alzheimer’s Disease

Specific Aims

The Alzheimer's Disease trial is a randomized, parallel group, double-blinded study comparing treatment with olanzapine, quetiazpine, risperidone, and placebo in AD patients with delusions or hallucinations AND/OR clinically significant aggression or agitation.

1. To compare the acute efficacy and effectiveness of risperidone, olanzapine, and quetiapine in treatment algorithms over the course of 36 weeks in treating psychosis in outpatients with Alzheimer's disease.
2. To assess their relative effectiveness at maintaining clinical improvement up to 36 weeks.